Perspectives on blastomycosis in Canada in the face of climate change

CCDR: Volume 50-11(4), November 2024: cover image

Download this article as a PDF (189 KB)
Published by: The Public Health Agency of Canada
Issue: CCDR Volume 50-11, November 2024: Influenza Vaccination
Date published: November 2024
ISSN: 1481-8531

Subscribe to CCDR

Submit a manuscript

Information for authors

About CCDR

Browse

Past issues

Volume 50-11, November 2024: Influenza Vaccination

Overview

Perspectives on blastomycosis in Canada in the face of climate change

Amole Khadilkar¹, Lisa Waddell², Emily S Acheson^3,4, Nicholas H Ogden^3,4

Affiliations

¹ Environmental Public Health Division, Indigenous Services Canada, Ottawa, ON

² Public Health Risk Sciences, National Microbiology Laboratory Branch, Public Health Agency of Canada, Guelph, ON

³ Public Health Risk Sciences, National Microbiology Laboratory Branch, Public Health Agency of Canada, Saint-Hyacinthe, QC

⁴ Groupe de recherche en épidémiologie des zoonoses et santé publique (GREZOSP), Faculté de médecine vétérinaire, Université de Montréal, Montréal, QC

Correspondence

amole.khadilkar@sac-isc.gc.ca

Suggested citation

Khadilkar A, Waddell L, Acheson ES, Ogden NH. Perspectives on blastomycosis in Canada in the face of climate change. Can Commun Dis Rep 2024;50(11):400–11. https://doi.org/10.14745/ccdr.v50i11a04

Keywords: blastomycosis, endemic, Canada, climate change, ecological niche, thermally dimorphic fungi, geographic distribution

Abstract

Blastomycosis is a disease of potentially varied presentations caused by thermally dimorphic fungi that appear as mold at ambient temperatures and transform to yeast at body temperature. Inhalation of aerosolized fungal spores represents the primary mode of transmission. Exposure may follow outdoor activities that disturb soil, which is warm, moist, acidic and rich in organic debris, particularly within forested areas and in proximity to waterways. Blastomycosis is endemic to several parts of Canada, but is only reportable in Ontario and Manitoba, with Northwestern Ontario being considered a hyperendemic area with average annual incidence rates of over 25 cases per 100,000 population. Delays in diagnosis and treatment are frequently observed as the symptoms and imaging findings of blastomycosis may initially be mistaken for community-acquired pneumonia, tuberculosis or malignancy, which can result in interim disease progression and worsening clinical outcomes. Risks from fungal infections such as blastomycosis are likely to increase with climate change-associated shifts in temperature and rainfall, and this may contribute to the geographic expansion of cases, a phenomenon that appears to be already underway. Further research investigating the ecological niche of Blastomyces and its climate sensitivity could help facilitate better modelling of the potential impacts of climate change on risks to Canadians and inform more effective methods of exposure prevention. Early clinical recognition and treatment of blastomycosis remain the key to minimizing morbidity and mortality.

Introduction

Background

Blastomycosis is endemic to North America, particularly in areas bordering the Great Lakes, St. Lawrence Seaway and Mississippi and Ohio Rivers, though there is some evidence that the geographic distribution of blastomycosis is expanding beyond these historical margins ^{Footnote 1}^{Footnote 2}^{Footnote 3}^{Footnote 4}. Blastomyces dermatitidis and Blastomyces gilchristii are the predominant fungal species that cause blastomycosis in North America ^{Footnote 5}. Sporadic cases attributed to Blastomyces helicus have also been reported in western Canada and the United States (US), though these cases are characterized by an atypical geographic range, mycological features and clinical epidemiology ^{Footnote 6}^{Footnote 7}^{Footnote 8}. In contrast to cases associated with B. dermatitidis and B. gilchristii, which most frequently involve immunocompetent individuals, B. helicus is opportunistic, mainly affecting those who are immunocompromised ^{Footnote 6}^{Footnote 7}^{Footnote 8}. Other species that have been described include 1) B. percursus, found in Africa and the Middle East; 2) B. emzantsi, found in South Africa; 3) B. parvus, reported to cause a rare pulmonary illness distinct from blastomycosis, called adiaspiromycosis, in North and South America, Eastern Europe and Australia; and 4) B. silverae, which has been identified in western Canada and is not currently known to cause disease in humans ^{Footnote 8}^{Footnote 9}^{Footnote 10}. Blastomyces dermatitidis and B. gilchristii, the more commonly encountered Blastomyces spp. in North America, are examples of thermally dimorphic fungi that grow as mold in the environment at ambient temperatures, but which, once spores and mold fragments are released into the air and inhaled, convert to thick-walled, broad-based budding yeast at body temperature in tissues, resulting in morbidity in approximately half of infected individuals ^{Footnote 11}^{Footnote 12}.

Objectives

As the burden of blastomycosis in Canada is likely under-recognized and under-reported, the objective of this overview was to synthesize the clinical and epidemiological evidence regarding blastomycosis in Canada to improve awareness about this disease, highlighting the potential impacts of climate change as well as current knowledge gaps and future directions.

Methods

This literature review included a search for articles in PubMed and EBSCOhost databases using keywords related to blastomycosis and narrowed to literature conducted in North America from January 1, 2010, to June 9, 2024. The search was augmented by the evaluation of reference lists from the Health of Canadians in a Changing Climate report ^{Footnote 13} and several relevant primary research studies and literature reviews (available upon request) to identify work omitted by the database search until we reached saturation. Grey literature was identified by implementing the search strategy in Google and screening the search results, stopping at the point where no new relevant results were identified on a page, and through targeted searches within the websites of key public health agencies in North America. Citations were screened for relevance and inclusion in the review with a focus on evidence from Canada. Where applicable, citations for older evidence were replaced by newer evidence to ensure this review was a good reflection of the most recent evidence on blastomycosis.

Discussion

Incidence and trends in Canada

Within Canada, blastomycosis has been detected in areas of Ontario, Québec, Manitoba, Saskatchewan, Alberta, Nova Scotia and New Brunswick, but is only a reportable disease in Ontario as of mid-2018 and in Manitoba since 2006 ^{Footnote 11}^{Footnote 14}^{Footnote 15}^{Footnote 16}^{Footnote 17}^{Footnote 18}^{Footnote 19}^{Footnote 20}^{Footnote 21}^{Footnote 22}^{Footnote 23}. In endemic areas, where the disease is reportable, incidence rates typically are 0.4–1.3 cases per 100,000 population per year ^{Footnote 22}^{Footnote 24}^{Footnote 25}; however, hyperendemic areas such as Northwestern Ontario, represented by the catchment area of the Northwestern Health Unit, have reported average incidence rates of over 25 cases per 100,000 population per year (range: 15–43 cases per 100,000 population per year) ^{Footnote 21}^{Footnote 26}^{Footnote 27}^{Footnote 28}. In comparison, blastomycosis in the US is reportable in Arkansas, Louisiana, Colorado, Michigan, Minnesota and Wisconsin, where the annual incidence is two or fewer cases per 100,000 population, while hyperendemic areas in several northern counties of Wisconsin report annual rates in the range of 10–40 cases per 100,000 population ^{Footnote 29}^{Footnote 30}^{Footnote 31}. Given that blastomycosis is not a nationally notifiable disease either in Canada or the US, and in light of frequent asymptomatic infections and missed or delayed diagnoses, there is likely significant under-reporting of cases and under-estimation of its true incidence ^{Footnote 12}^{Footnote 32}^{Footnote 33}^{Footnote 34}^{Footnote 35}^{Footnote 36}.

Although there has not been consistent surveillance in affected areas of Canada to establish definite trends in the incidence of blastomycosis, several studies suggest that cases have been increasing in some areas over time ^{Footnote 14}^{Footnote 15}^{Footnote 33}^{Footnote 37}. The observed increases may be due to improving surveillance, increasing healthcare provider and/or community awareness of the infection, or possibly an expanding ecological niche for Blastomyces ^{Footnote 33}^{Footnote 37}^{Footnote 38}. It has been suggested that cases in dogs, whose incidence is estimated to be eight times greater than that of humans, may serve as sentinels for cases in humans ^{Footnote 39}^{Footnote 40}^{Footnote 41}^{Footnote 42}. The high incidence in dogs could be related to the time spent outdoors, close contact with soil and such behaviours as digging and sniffing, which can increase exposure to fungal spores ^{Footnote 40}.

Epidemiological investigations suggest most human cases of blastomycosis are sporadic; however, a smaller proportion occur as outbreaks with epidemiologic links to a likely common source ^{Footnote 29}^{Footnote 36}^{Footnote 43}^{Footnote 44}. Canadians are most commonly exposed during the warmer summer months when both the climate and human activities are more favourable for exposure; this leads to a majority of cases being diagnosed in the fall and winter, following an appropriate incubation period ^{Footnote 11}^{Footnote 14}^{Footnote 33}^{Footnote 45}^{Footnote 46}^{Footnote 47}^{Footnote 48}. In the US, no seasonal pattern was observed for blastomycosis-related hospital admissions during the period 2010–2020 ^{Footnote 49}.

Ecological factors

The ecology of Blastomyces is not well understood due to challenges in conducting epidemiological investigations that aim to identify a potential source, given the long latency period of up to 15 weeks from exposure to clinical onset ^{Footnote 31}. Further challenges exist in recovering the fungus from the environment as Blastomyces is found to compete poorly with other microflora present in natural soil ^{Footnote 38}^{Footnote 50}^{Footnote 51}^{Footnote 52}. Studies have reported the failure to repeat the isolation of Blastomyces at later time points from previously positive sample sites, suggesting that its growth can be sporadic and perhaps contingent on short-lived climactic and environmental conditions ^{Footnote 52}^{Footnote 53}. Large outbreaks over an extended duration have been reported where optimal growth conditions are presumably stable, such as an outbreak spanning 10 weeks in Wisconsin in 2015 associated with recreational tubing along a river ^{Footnote 54}.

To date, research characterizing the environmental niche of Blastomyces suggests that moist soil with high organic content (e.g., rotting wood, decaying vegetation, animal manure) and acidic pH near lakes and rivers or in wooded areas is well suited for Blastomyces spp. survival ^{Footnote 52}^{Footnote 53}^{Footnote 55}^{Footnote 56}^{Footnote 57}^{Footnote 58}. Laboratory and outbreak investigations also indicate that recent rainfall is important for the recovery of Blastomyces from environmental samples and the release of spores into the environment, which are then dispersed during windy weather ^{Footnote 52}^{Footnote 56}^{Footnote 59}^{Footnote 60}^{Footnote 61}^{Footnote 62}. While outbreaks have occurred in the relative absence of rain too, other factors may have been present that created favourable conditions for transmission, such as proximity to waterways and/or soil-disrupting activity ^{Footnote 54}^{Footnote 63}.

Risk groups

Risk of exposure can increase with human activities that disturb soil and aerosolize spores, including occupations involving high-risk outdoor activities such as construction, excavation, landscaping and forestry work ^{Footnote 1}^{Footnote 34}^{Footnote 38}^{Footnote 48}^{Footnote 57}^{Footnote 60}^{Footnote 64}^{Footnote 65}^{Footnote 66}^{Footnote 67}. Other exposures may come from outdoor recreational activities, including hunting, fishing, canoeing, camping, hiking and the use of all-terrain vehicles (ATVs), which involve close contact with soil and decaying vegetation near waterways ^{Footnote 1}^{Footnote 38}^{Footnote 46}^{Footnote 55}^{Footnote 64}^{Footnote 68}^{Footnote 69}.

The majority of clinical cases occur in adults (mostly middle-aged adults 30–59 years of age) with less than 13% occurring in children ^{Footnote 11}^{Footnote 12}^{Footnote 14}^{Footnote 16}^{Footnote 26}^{Footnote 45}^{Footnote 62}^{Footnote 70}. Males are more frequently affected than females, which may reflect a greater likelihood of occupational or recreational environmental exposures ^{Footnote 38}; however, a sex-specific, possibly hormonally mediated, susceptibility to infection has been proposed as a factor in another endemic dimorphic mycosis that predominates in males, namely coccidioidomycosis ^{Footnote 71}^{Footnote 72}.

Indigenous Peoples in Ontario and Manitoba have been found to be disproportionately affected by blastomycosis ^{Footnote 11}^{Footnote 33}^{Footnote 46}. Similarly, in the US, incidence rates among Native American and Alaska Native Peoples between 2010 and 2020 were approximately six times higher than in non-Hispanic Whites ^{Footnote 71}. A genetic predisposition may account for these findings, but alternate explanations include differences in occupational or recreational exposures, access to medical care, socioeconomic status and/or other social determinants of health ^{Footnote 12}^{Footnote 36}^{Footnote 38}^{Footnote 71}. Higher rates of comorbidities and smoking among Indigenous Peoples in Northwestern Ontario were also offered as possible contributing factors ^{Footnote 33}.

Clinical features of blastomycosis

The primary route of Blastomyces transmission is through the inhalation of aerosolized spores; however, infection has also been documented from direct cutaneous inoculation by traumatic injury (e.g., needlestick injuries in laboratory workers or veterinarians) or following a bite or scratch from an infected animal ^{Footnote 73}^{Footnote 74}^{Footnote 75}^{Footnote 76}. Isolated case reports of possible sexual transmission appear in the literature, along with rare reports of perinatal transmission ^{Footnote 77}^{Footnote 78}^{Footnote 79}^{Footnote 80}^{Footnote 81}.

The incubation period of blastomycosis is estimated to be 30 to 45 days for inhalational exposure with a possible range of 14 to 106 days, whereas the incubation period for primary cutaneous inoculation is approximately two weeks ^{Footnote 26}^{Footnote 54}^{Footnote 55}^{Footnote 73}^{Footnote 78}.

The clinical spectrum of disease includes subclinical infection in approximately 50% of cases; acute pneumonia, indistinguishable from community-acquired bacterial pneumonia; chronic pneumonia, mimicking tuberculosis (cavitary lesions, miliary pattern) or malignancy (nodules, masses); and, at the most severe end of the spectrum, lung infection may progress to acute respiratory distress syndrome (ARDS) in 8%–15% of cases ^{Footnote 7}^{Footnote 8}^{Footnote 55}^{Footnote 82}^{Footnote 83}^{Footnote 84}. Symptoms of acute pulmonary blastomycosis consist of fever, chills, headache, productive or non-productive cough, shortness of breath, chest pain and malaise ^{Footnote 12}. Symptoms of chronic pulmonary blastomycosis include fever, chills, persistent cough, hemoptysis, night sweats, decreased appetite and weight loss, which can be readily mistaken for the clinical signs of tuberculosis or cancer ^{Footnote 12}. Hematogenous dissemination occurs in 25%–40% of cases ^{Footnote 12}. Upon dissemination, any organ can potentially become involved, though the most commonly affected organ systems are the skin, followed by the bones and joints (e.g., long bones, thoracolumbar spine, ribs, skull), genitourinary tract (e.g., prostatitis, epididymo-orchitis) and central nervous system (CNS), where blastomycosis can present as meningitis, epidural abscesses, intracranial abscesses or other space-occupying lesions (i.e., granulomas) ^{Footnote 34}^{Footnote 43}^{Footnote 85}^{Footnote 86}^{Footnote 87}^{Footnote 88}. Cutaneous disease may appear as single or multiple verrucous, nodular or ulcerative lesions on the face and distal extremities that are often marked by sharp, irregular borders, crusting and the formation of micro-abscesses in the underlying subcutaneous tissue ^{Footnote 43}^{Footnote 89}.

The variety of clinical presentations of blastomycosis and their similarities to other conditions present challenges to early diagnosis. In a retrospective chart review, a median of 2.5 courses of antibiotics (interquartile range [IQR]: 1.5–4.5 courses) were prescribed prior to a diagnosis of pulmonary blastomycosis and a median of 23 days (IQR: 8–36 days) passed from the initial presentation to a healthcare facility before the correct diagnosis was made ^{Footnote 35}. Like pulmonary blastomycosis, cutaneous blastomycosis is often misdiagnosed as other pathologies such as basal cell or squamous cell carcinoma, keratoacanthoma, pyoderma gangrenosum (associated with autoimmune disease) or cutaneous tuberculosis ^{Footnote 7}^{Footnote 76}^{Footnote 90}^{Footnote 91}. Osteomyelitis resulting from Blastomyces infection can mimic cancer (appearing as masses or lytic lesions on imaging) or skeletal tuberculosis ^{Footnote 7}. Further underpinning its reputation as a great masquerader, meningitis due to disseminated blastomycosis is frequently misdiagnosed as tuberculous meningitis, while blastomycosis-associated spinal or intracranial space-occupying lesions can be mistaken for malignancy ^{Footnote 7}^{Footnote 86}^{Footnote 87}^{Footnote 88}^{Footnote 92}.

A few studies have reported on the differences in clinical presentation and/or clinical severity between cases infected with B. dermatitidis compared to B. gilchristii. One study conducted in Québec, Canada found no association between Blastomyces genotype and the proportion of severe or fatal cases; however, only 2% of the patients in their sample were infected with B. gilchristii, reducing its power to discriminate clinically between species ^{Footnote 93}. A more recent study conducted in Wisconsin found that patients infected with B. gilchristii (n=80) were more likely to be hospitalized than those with B. dermatitidis (n=40), though the difference was no longer statistically significant following multivariate regression analysis (p=0.06) ^{Footnote 94}. Additional variation in clinical presentations between species was noted, where patients infected with B. gilchristii were more likely to present with fever (p<0.05) and those with B. dermatitidis had a significantly higher rate of developing disseminated infection with skin lesions (p<0.05) ^{Footnote 94}.

The mortality rate for blastomycosis was estimated in a 2020 systematic review and meta-analysis, which found an overall pooled mortality of 6.6% (95% CI: 4.9%–8.2%) across diagnosed cases of blastomycosis ^{Footnote 32}. This estimate is in relative agreement with studies from the US that estimated mortality to be 6.9%–10% ^{Footnote 36}^{Footnote 49}^{Footnote 68}^{Footnote 71}^{Footnote 95}; however, the US Centers for Disease Control and Prevention recently reported that the case fatality rate for blastomycosis across the five states where the disease was reportable rose to 17% in 2021, almost double the rate in 2019 ^{Footnote 96}. This sharp jump may be related to overwhelmed healthcare systems during the pandemic and patient hesitancy to seek medical care, which may have exacerbated diagnostic and treatment delays, leading to more severe disease presentations ^{Footnote 96}.

Risk factors associated with mortality and/or severe disease have included older age, immunosuppression, multi-lobar pulmonary involvement, ARDS and chronic disease (e.g., malignancy, chronic obstructive pulmonary disease, chronic lung disease, obesity, diabetes) ^{Footnote 32}^{Footnote 49}^{Footnote 68}^{Footnote 93}^{Footnote 97}. While the current evidence suggests that being immunocompromised is not a risk factor for developing blastomycosis, infection is more severe among those who are immunocompromised ^{Footnote 34}. The previously cited meta-analysis found that the pooled mortality rate was more than five times higher among patients who were immunocompromised (37%; 95% CI: 23%–51%) compared to general patients (6.6%; 95% CI: 4.9%–8.2%) ^{Footnote 32}. When complicated by ARDS, the mortality rate of blastomycosis reached 75% (95% CI: 53%–96%) ^{Footnote 32}.

Laboratory diagnosis

The gold standard for the diagnosis of blastomycosis is by culture of sputum, tracheal aspirates, bronchoalveolar lavage fluid, cerebrospinal fluid, urine or biopsied tissue, but results can take 1–4 weeks ^{Footnote 34}. Microscopic visualization of yeast cells in smears or tissue specimens following the application of 10% potassium hydroxide and/or a fungal stain can offer a more rapid diagnosis, but this method is less sensitive than culture, so a negative result does not exclude a diagnosis of blastomycosis ^{Footnote 38}.

Serological tests have been available for decades, but their diagnostic value is limited by poor sensitivity, particularly early in infection and among patients who are immunocompromised ^{Footnote 38}^{Footnote 81}^{Footnote 98}. The most sensitive antibody test consisted of an enzyme immunoassay (EIA) that detected antibodies against Blastomyces adhesin-1 (BAD-1), a cell wall adhesion antigen and virulence factor. Despite a reported sensitivity of 88% and specificity of 94%–99%, this test has not gained widespread clinical use ^{Footnote 7}^{Footnote 99}.

Enzyme immunoassays detecting a cell wall antigen known as galactomannan in patient body fluids have become a useful diagnostic tool that enables the rapid diagnosis of blastomycosis from a range of samples, including urine, serum, bronchoalveolar lavage fluid or cerebrospinal fluid ^{Footnote 8}^{Footnote 12}. In the US, antigen EIA is a recommended component of diagnostic testing for suspected blastomycosis ^{Footnote 98}^{Footnote 100}; however, in Canada, the adoption of antigen EIAs is reported to be limited ^{Footnote 81}. The sensitivity of antigen detection by EIA in urine samples of patients with proven disease is 76.3%–92.9% and the specificity is 79.3%, while the sensitivity of antigen EIA using serum as the sample source is somewhat lower, ranging from 56%–82% ^{Footnote 98Footnote 100}^{Footnote 101}^{Footnote 102}^{Footnote 103}. False-positives can occur due to cross-reactivity with other fungal pathogens, particularly Histoplasma, which can be an issue in areas where their respective geographic distributions overlap; fortunately, the recommended treatments for histoplasmosis and blastomycosis are similar, reducing the harm of misdiagnosis ^{Footnote 5}^{Footnote 100}^{Footnote 101}^{Footnote 104}^{Footnote 105}. Note that serologic testing may be helpful for differentiating blastomycosis from histoplasmosis and on occasions when antigen EIAs are negative but suspicion for blastomycosis remains ^{Footnote 98}. It has been suggested that antigen EIA levels may correlate with disease severity and could be used to monitor the response to blastomycosis treatment, but at least with respect to antigen testing for histoplasmosis, low levels of antigenuria may persist in some patients for months even after successful eradication ^{Footnote 8}^{Footnote 34}^{Footnote 104}^{Footnote 106}^{Footnote 107}.

Advances in the molecular diagnosis of Blastomyces infection could help facilitate the workup of patients with possible blastomycosis and reduce diagnostic delays; however PCR-based tests are currently limited to reference laboratories and have not been widely standardized ^{Footnote 7}^{Footnote 34}^{Footnote 106}.

Given the imperfect sensitivity and specificity of currently available tests, no single test is sufficiently accurate for diagnosis in isolation ^{Footnote 100}. In combination with clinical and epidemiological history, physicians often need to use multiple diagnostic methods to get an acceptable level of diagnostic accuracy ^{Footnote 98}^{Footnote 100}.

Treatment

All patients diagnosed with blastomycosis should receive antifungal therapy regardless of the clinical presentation because of the risk of progression or recurrence of symptoms if left untreated ^{Footnote 34}. Mild to moderate blastomycosis is treated with oral itraconazole, while moderate to severe blastomycosis is initially treated with lipid formulations of amphotericin B for 1–2 weeks until clinical improvement is noted (4–6 weeks in the case of CNS disease), following which, therapy is completed using oral itraconazole ^{Footnote 34}^{Footnote 104}. Total treatment duration is typically 6–12 months and depends on the severity of the infection, immune status of the host and involvement of the bone, joints or CNS ^{Footnote 7}^{Footnote 34}^{Footnote 104}. Lifelong suppressive therapy with oral itraconazole may be required for immunosuppressed patients if immunosuppression cannot be reversed ^{Footnote 104}.

Several other azoles have been used to treat blastomycosis; however, clinical trial data for these other agents is still limited. For example, a novel formulation of itraconazole is available, called super-bioavailability itraconazole (SUBA-itra), which exhibits enhanced intestinal absorption relative to the conventional formulation with reduced inter-patient pharmacokinetic variability and a lower impact from food and alterations in gastric acidity ^{Footnote 108}. Voriconazole, a relatively newer azole, has been shown to be effective as an alternative to itraconazole when there is CNS involvement due to its better penetration of the blood brain barrier and excellent in vitro activity against B. dermatitidis, followed by fluconazole, which also demonstrates good penetration into the CNS and is moderately effective against blastomycosis ^{Footnote 8}^{Footnote 92}^{Footnote 104}. Another relatively newer azole, posaconazole, has been used to treat non-CNS blastomycosis, as it penetrates the blood brain barrier poorly but may have more potent fungicidal activity against Blastomyces than itraconazole as well as improved oral absorption and fewer adverse effects ^{Footnote 8}^{Footnote 109}. Limited data for oral isavuconazole also exist ^{Footnote 7}^{Footnote 8}^{Footnote 110}. Given their narrow therapeutic windows, therapeutic drug monitoring is recommended when using either itraconazole, voriconazole or posaconazole in order to ensure adequate steady-state serum levels and avoid drug-related toxicities ^{Footnote 111}.

Pregnant patients who are diagnosed with blastomycosis should receive intravenous liposomal amphotericin B without a subsequent azole, due to the teratogenic effects of azoles, until after delivery or until resolution of the infection, whichever occurs first ^{Footnote 7}. Post-delivery, the placenta should be examined for signs of Blastomyces infection, the newborn monitored closely and amphotericin B deoxycholate given if the newborn is found to be infected ^{Footnote 7}.

Impacts of climate change

The future climate projected for Canada includes increasing temperatures, increasing rainfall (although with more regional variation than for temperature) and a greater fraction of precipitation during the winter occurring as rain rather than snow ^{Footnote 13}^{Footnote 112}. The climate is also expected to become more variable, with an increase in extreme weather events, including heat waves, summertime droughts and more frequent and severe storms that are expected to increase the possibility of flooding ^{Footnote 13}^{Footnote 112}. Risks from fungal infections such as blastomycosis are likely to change with these expected changes in temperature and rainfall ^{Footnote 4}^{Footnote 13}. Globally, over half of known infectious diseases (n=218/375) were found to be potentially exacerbated by the effects of climate change, including blastomycosis and twenty-three other fungal diseases ^{Footnote 113}. Climate change may also drive changes to the geographic ranges of several dimorphic fungi that are endemic to North America, such as Coccidioides in Southwestern US and Histoplasma and Blastomyces in the US and Canada ^{Footnote 3}^{Footnote 4}^{Footnote 114}^{Footnote 115}^{Footnote 116}. These changes may be long-lasting or, perhaps, transient and variable. A study conducted in Minnesota reported the transient detection of Blastomyces DNA in environmental samples obtained from a non-endemic location following a flood, pointing, once again, to the sometimes evanescent nature of this fungal pathogen when short-term climactic conditions transiently favour fungal growth in otherwise non-conducive environments ^{Footnote 117}. Climate change may also impact the frequency of cases, and an association between flooding and frequency of blastomycosis cases has been described in the literature ^{Footnote 117}^{Footnote 118}^{Footnote 119}^{Footnote 120}.

Greer et al. speculated that the dry summers and heavy wintertime precipitation projected for North America would provide optimal conditions for the dispersal of Blastomyces spores ^{Footnote 121}. Panackal further pointed out that a common pattern emerges among fungal species, in which growth is facilitated by soil moisture from precipitation and humidity, followed by a dry period when fungal hyphae desiccate and form spores, culminating with windy conditions, potentially in the form of storms, hurricanes and tornados, which then aerosolize and disperse the spores over great distances ^{Footnote 122}. Among several blastomycosis case clusters reported in the literature, exposure was considered to have occurred following periods of diminished precipitation or drought and in association with rainfall events, reinforcing the significance of dry and wet cycles ^{Footnote 38}^{Footnote 55}^{Footnote 56}^{Footnote 57}^{Footnote 61}^{Footnote 62}^{Footnote 63}^{Footnote 123}. During abnormally dry days, whose frequency, intensity and duration will increase as the climate continues to grow warmer, winds can disperse fungal spores in the same way that they spread pollen ^{Footnote 13}.

Conclusion

This review summarizes the evidence regarding blastomycosis in Canada and highlights what is currently known and where important knowledge gaps exist for this fungal disease. While projected to have a larger public health impact due to climate change-associated shifts in temperature and rainfall, our understanding of the interplay between blastomycosis and environmental factors is far from complete ^{Footnote 2}^{Footnote 3}^{Footnote 4}^{Footnote 13}^{Footnote 121}^{Footnote 122}^{Footnote 123}^{Footnote 124}^{Footnote 125}^{Footnote 126}^{Footnote 127}^{Footnote 128}. Further study of Blastomyces’ ecological niche and climate sensitivity will require novel approaches and greater laboratory test capacity to isolate the pathogen from the environment ^{Footnote 129}. This could, in turn, facilitate improved modelling of the potential impacts of climate change on risks to the public and help inform more effective measures for prevention ^{Footnote 38}.

Bearing in mind the uncertainties concerning the current and future epidemiology of blastomycosis, the most important factor in limiting morbidity and mortality is increasing healthcare providers’ awareness of blastomycosis to ensure timely diagnosis and treatment and prevent more serious progression of disease. In the event of outbreaks, early clinical recognition also leads to the early engagement of public health authorities, who can introduce measures to limit ongoing exposures and prevent new cases. Finally, increased awareness among the public living in endemic/hyperendemic areas, particularly those at higher risk, such as Indigenous Peoples and individuals who are immunocompromised, can empower them to ask their healthcare providers about the possibility of blastomycosis should they develop compatible symptoms.

In addition to promoting greater education and awareness, other key measures to consider include the following: funding research to close knowledge gaps regarding the ecology of Blastomyces; improving surveillance by making blastomycosis more widely reportable; developing rapid, accurate and standardized PCR-based assays to improve timely case detection; exploring the potential of computer-aided diagnosis using artificial intelligence and machine learning models that could prompt physicians to consider blastomycosis early in the diagnostic process ^{Footnote 111}^{Footnote 130}^{Footnote 131}; and finally, developing safer and better-tolerated antifungal treatments to maximize treatment adherence, especially in view of the prolonged length of therapy that can be required for this disease.

Authors' statement

AK — Principal writer, writing–original draft, writing–review & editing
LW — Writing–review & editing
ESA — Writing–review & editing
NHO — Supervision, writing–review & editing

Competing interests

None.

Acknowledgements

The authors would like to acknowledge the contribution of Natacha Demers, who did preliminary research of the literature; Indigenous Services Canada Departmental Library’s information specialists, who retrieved dozens of articles that needed to be ordered through interlibrary loans; and Dr. James Brooks, who reviewed a very early version of this work and provided valuable feedback.

Funding

None.

References

Footnote 1

Public Health Agency of Canada. Risks of blastomycosis. Ottawa, ON: PHAC; 2016. https://www.canada.ca/en/public-health/services/diseases/blastomycosis/risks-blastomycosis.html

Return to footnote 1 referrer

Footnote 2

Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW, Wright L, McCotter O, Schwartz IS, Jackson BR, Chiller T, Bahr NC. Re-drawing the Maps for Endemic Mycoses. Mycopathologia 2020;185(5):843–65. https://doi.org/10.1007/s11046-020-00431-2

Return to footnote 2 referrer

Footnote 3

Mazi PB, Sahrmann JM, Olsen MA, Coler-Reilly A, Rauseo AM, Pullen M, Zuniga-Moya JC, Powderly WG, Spec A. The Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era. Clin Infect Dis 2023;76(7):1295–301. https://doi.org/10.1093/cid/ciac882

Return to footnote 3 referrer

Footnote 4

Thompson GR 3rd, Chiller TM. Endemic Mycoses: underdiagnosed and Underreported. Ann Intern Med 2022;175(12):1759–60. https://doi.org/10.7326/M22-2371

Return to footnote 4 referrer

Footnote 5

Mazi PB, Rauseo AM, Spec A. Blastomycosis. Infect Dis Clin North Am 2021;35(2):515–30. https://doi.org/10.1016/j.idc.2021.03.013

Return to footnote 5 referrer

Footnote 6

Schwartz IS, Wiederhold NP, Hanson KE, Patterson TF, Sigler L. Blastomyces helicus, a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and the United States. Clin Infect Dis 2019;68(2):188–95. https://doi.org/10.1093/cid/ciy483

Return to footnote 6 referrer

Footnote 7

Pullen MF, Alpern JD, Bahr NC. Blastomycosis-Some Progress but Still Much to Learn. J Fungi (Basel) 2022;8(8):824. https://doi.org/10.3390/jof8080824

Return to footnote 7 referrer

Footnote 8

Linder KA, Kauffman CA, Miceli MH. Blastomycosis: A Review of Mycological and Clinical Aspects. J Fungi (Basel) 2023;9(1):117. https://doi.org/10.3390/jof9010117

Return to footnote 8 referrer

Footnote 9

Schwartz IS, Muñoz JF, Kenyon CR, Govender NP, McTaggart L, Maphanga TG, Richardson S, Becker P, Cuomo CA, McEwen JG, Sigler L. Blastomycosis in Africa and the Middle East: A Comprehensive Review of Reported Cases and Reanalysis of Historical Isolates Based on Molecular Data. Clin Infect Dis 2021;73(7):e1560–9. https://doi.org/10.1093/cid/ciaa1100

Return to footnote 9 referrer

Footnote 10

Maphanga TG, Birkhead M, Muñoz JF, Allam M, Zulu TG, Cuomo CA, Schwartz IS, Ismail A, Naicker SD, Mpembe RS, Corcoran C, de Hoog S, Kenyon C, Borman AM, Frean JA, Govender NP. Human Blastomycosis in South Africa Caused by Blastomyces percursus and Blastomyces emzantsi sp. nov., 1967 to 2014. J Clin Microbiol 2020;58(3):e01661–19. https://doi.org/10.1128/JCM.01661-19

Return to footnote 10 referrer

Footnote 11

Crampton TL, Light RB, Berg GM, Meyers MP, Schroeder GC, Hershfield ES, Embil JM. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 2002;34(10):1310–6. https://doi.org/10.1086/340049

Return to footnote 11 referrer

Footnote 12

McBride JA, Gauthier GM, Klein BS. Clinical Manifestations and Treatment of Blastomycosis. Clin Chest Med 2017;38(3):435–49. https://doi.org/10.1016/j.ccm.2017.04.006

Return to footnote 12 referrer

Footnote 13

Health Canada. Health of Canadians in a Changing Climate: Advancing our Knowledge for Action. Ottawa, ON: HC; 2022. https://changingclimate.ca/site/assets/uploads/sites/5/2022/02/CCHA-REPORT-EN.pdf

Return to footnote 13 referrer

Footnote 14

Brown EM, McTaggart LR, Dunn D, Pszczolko E, Tsui KG, Morris SK, Stephens D, Kus JV, Richardson SE. Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990-2015. Emerg Infect Dis 2018;24(7):1257–66. https://doi.org/10.3201/eid2407.172063

Return to footnote 14 referrer

Footnote 15

Litvinov IV, St-Germain G, Pelletier R, Paradis M, Sheppard DC. Endemic human blastomycosis in Quebec, Canada, 1988-2011. Epidemiol Infect 2013;141(6):1143–7. https://doi.org/10.1017/S0950268812001860

Return to footnote 15 referrer

Footnote 16

Lohrenz S, Minion J, Pandey M, Karunakaran K. Blastomycosis in Southern Saskatchewan 2000-2015: unique presentations and disease characteristics. Med Mycol 2018;56(7):787–95. https://doi.org/10.1093/mmy/myx131

Return to footnote 16 referrer

Footnote 17

Vallabh V, Martin T, Conly JM. Blastomycosis in Saskatchewan. West J Med 1988;148(4):460–2.

Return to footnote 17 referrer

Footnote 18

Sekhon AS, Bogorus MS, Sims HV. Blastomycosis: report of three cases from Alberta with a review of Canadian cases. Mycopathologia 1979;68(1):53–63. https://doi.org/10.1007/BF00490391

Return to footnote 18 referrer

Footnote 19

Ross JJ, Keeling DN. Cutaneous blastomycosis in New Brunswick: case report. CMAJ 2000;163:1303–5. https://www.cmaj.ca/content/163/10/1303

Return to footnote 19 referrer

Footnote 20

Nicolle L, Rotstein C, Bourgault A, St-Germain G, Garber G; Canadian Infectious Diseases Society Invasive Fungal Registry. Invasive fungal infections in Canada from 1992 to 1994. Can J Infect Dis 1998;9(6):347–52. https://doi.org/10.1155/1998/473219

Return to footnote 20 referrer

Footnote 21

Ottawa Public Health. Blastomycosis. Ottawa, ON: OPH; 2024. https://www.ottawapublichealth.ca/en/professionals-and-partners/blastomycosis-hcp.aspx#Local-Epidemiology

Return to footnote 21 referrer

Footnote 22

Public Health Ontario. Infectious Disease Trends in Ontario. Toronto, ON: PHO; 2023. https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/reportable-disease-trends-annually#/67

Return to footnote 22 referrer

Footnote 23

Government of Manitoba. Re: Blastomycosis Reporting and Case Investigation. Winnipeg, MB: Government of Manitoba; 2015. https://www.gov.mb.ca/health/publichealth/cdc/protocol/blastomycosis.pdf

Return to footnote 23 referrer

Footnote 24

Public Health Ontario. Surveillance: Diseases of Public Health Significance Cases for January to December 2023. Toronto, ON: PHO; 2024. https://www.publichealthontario.ca/-/media/Documents/Surveillance-Reports/Infectious/2023/surveillance-report-infectious-diseases-2023.pdf?rev=497c49973fda4883aa5a7d7577fe6e88&sc_lang=en

Return to footnote 24 referrer

Footnote 25

Government of Manitoba. Manitoba Annual Summary of Communicable Diseases 2017. Winnipeg, MB: Government of Manitoba; 2019. https://www.gov.mb.ca/health/publichealth/surveillance/cds/docs/2017.pdf

Return to footnote 25 referrer

Footnote 26

Litvinjenko S, Lunny D. Blastomycosis hospitalizations in northwestern Ontario: 2006-2015. Can Commun Dis Rep 2017;43(10):200–5. https://doi.org/10.14745/ccdr.v43i10a02

Return to footnote 26 referrer

Footnote 27

Northwestern Health Unit. Blastomycosis Information for Health Care Providers. Kenora, ON: NWHU; 2023. https://www.nwhu.on.ca/for-professionals/for-health-care-professionals/blastomycosis-information-for-health-care-providers/

Return to footnote 27 referrer

Footnote 28

Northwestern Health Unit. Regional Blastomycosis Backgrounder for Health Care Providers. Kenora, ON: NWHU; 2023. [Accessed 2024 Sept 3]. https://www.nwhu.on.ca/wp-content/uploads/2022/11/Blastomycosis-presentations-OCT-2022.pdf

Return to footnote 28 referrer

Footnote 29

Centers for Disease Control and Prevention. Data and Statistics on Blastomycosis. Atlanta, GA: CDC; 2024. https://www.cdc.gov/blastomycosis/data-research/statistics/index.html

Return to footnote 29 referrer

Footnote 30

Centers for Disease Control and Prevention. Reportable Fungal Diseases by State. Atlanta, GA: CDC; 2024. https://www.cdc.gov/fungal/php/case-reporting/index.html

Return to footnote 30 referrer

Footnote 31

Reed KD, Meece JK, Archer JR, Peterson AT. Ecologic niche modeling of Blastomyces dermatitidis in Wisconsin. PLoS One 2008;3(4):e2034. https://doi.org/10.1371/journal.pone.0002034

Return to footnote 31 referrer

Footnote 32

Carignan A, Denis M, Abou Chakra CN. Mortality associated with Blastomyces dermatitidis infection: A systematic review of the literature and meta-analysis. Med Mycol 2020;58(1):1–10. https://doi.org/10.1093/mmy/myz048

Return to footnote 32 referrer

Footnote 33

Dalcin D, Ahmed SZ. Blastomycosis in northwestern Ontario, 2004 to 2014. Can J Infect Dis Med Microbiol 2015;26(5):259–62. https://doi.org/10.1155/2015/468453

Return to footnote 33 referrer

Footnote 34

Castillo CG, Kauffman CA, Miceli MH. Blastomycosis. Infect Dis Clin North Am 2016;30(1):247–64. https://doi.org/10.1016/j.idc.2015.10.002

Return to footnote 34 referrer

Footnote 35

Alpern JD, Bahr NC, Vazquez-Benitez G, Boulware DR, Sellman JS, Sarosi GA. Diagnostic Delay and Antibiotic Overuse in Acute Pulmonary Blastomycosis. Open Forum Infect Dis 2016;3(2):ofw078. https://doi.org/10.1093/ofid/ofw078

Return to footnote 35 referrer

Footnote 36

Benedict K, Gibbons-Burgener S, Kocharian A, Ireland M, Rothfeldt L, Christophe N, Signs K, Jackson BR. Blastomycosis Surveillance in 5 States, United States, 1987-2018. Emerg Infect Dis 2021;27(4):999–1006. https://doi.org/10.3201/eid2704.204078

Return to footnote 36 referrer

Footnote 37

Davies JL, Epp T, Burgess HJ. Prevalence and geographic distribution of canine and feline blastomycosis in the Canadian prairies. Can Vet J 2013;54(8):753–60.

Return to footnote 37 referrer

Footnote 38

Benedict K, Roy M, Chiller T, Davis JP. Epidemiologic and ecologic features of blastomycosis: a review. Curr Fungal Infect Rep 2012;6:327–35. https://doi.org/10.1007/s12281-012-0110-1

Return to footnote 38 referrer

Footnote 39

Herrmann JA, Kostiuk SL, Dworkin MS, Johnson YJ. Temporal and spatial distribution of blastomycosis cases among humans and dogs in Illinois (2001-2007). J Am Vet Med Assoc 2011;239(3):335–43. https://doi.org/10.2460/javma.239.3.335

Return to footnote 39 referrer

Footnote 40

Schwartz IS. Blastomycosis in Mammals. In: Emerging and Epizootic Fungal Infections in Animals. Springer 2018;159–76. https://doi.org/10.1007/978-3-319-72093-7_8

Return to footnote 40 referrer

Footnote 41

Shelnutt LM, Kaneene JB, Carneiro PA, Langlois DK. Prevalence, distribution, and risk factors for canine blastomycosis in Michigan, USA. Med Mycol 2020;58(5):609–16. https://doi.org/10.1093/mmy/myz110

Return to footnote 41 referrer

Footnote 42

Sarosi GA, Eckman MR, Davies SF, Laskey WK. Canine blastomycosis as a harbinger of human disease. Ann Intern Med 1979;91(5):733–5. https://doi.org/10.7326/0003-4819-91-5-733

Return to footnote 42 referrer

Footnote 43

Bradsher RW Jr. The endemic mimic: blastomycosis an illness often misdiagnosed. Trans Am Clin Climatol Assoc 2014;125:188–202.

Return to footnote 43 referrer

Footnote 44

Thompson K, Sterkel AK, Brooks EG. Blastomycosis in Wisconsin: beyond the Outbreaks. Acad Forensic Pathol 2017;7(1):119–29. https://doi.org/10.23907/2017.014

Return to footnote 44 referrer

Footnote 45

Morris SK, Brophy J, Richardson SE, Summerbell R, Parkin PC, Jamieson F, Limerick B, Wiebe L, Ford-Jones EL. Blastomycosis in Ontario, 1994-2003. Emerg Infect Dis 2006;12(2):274–9. https://doi.org/10.3201/eid1202.050849

Return to footnote 45 referrer

Footnote 46

Dwight PJ, Naus M, Sarsfield P, Limerick B. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. Can Commun Dis Rep 2000;26(10):82–91.

Return to footnote 46 referrer

Footnote 47

Bruce Light R, Kralt D, Embil JM, Trepman E, Wiebe L, Limerick B, Sarsfield P, Hammond G, Macdonald K. Seasonal variations in the clinical presentation of pulmonary and extrapulmonary blastomycosis. Med Mycol 2008;46(8):835–41. https://doi.org/10.1080/13693780802132763

Return to footnote 47 referrer

Footnote 48

Baumgardner DJ, Buggy BP, Mattson BJ, Burdick JS, Ludwig D. Epidemiology of blastomycosis in a region of high endemicity in north central Wisconsin. Clin Infect Dis 1992;15(4):629–35. https://doi.org/10.1093/clind/15.4.629

Return to footnote 48 referrer

Footnote 49

Benedict K, Hennessee I, Gold JA, Smith DJ, Williams S, Toda M. Blastomycosis-Associated Hospitalizations, United States, 2010-2020. J Fungi (Basel) 2023;9(9):867. https://doi.org/10.3390/jof9090867

Return to footnote 49 referrer

Footnote 50

Schwartz IS, Kauffman CA. Blastomycosis. Semin Respir Crit Care Med 2020;41(1):31–41. https://doi.org/10.1055/s-0039-3400281

Return to footnote 50 referrer

Footnote 51

Baumgardner DJ, Paretsky DP, Baeseman ZJ, Schreiber A. Effects of season and weather on blastomycosis in dogs: northern Wisconsin, USA. Med Mycol 2011;49(1):49–55. https://doi.org/10.3109/13693786.2010.488658

Return to footnote 51 referrer

Footnote 52

Denton JF, DiSalvo AF. Additional isolations of Blastomyces dermatitidis from natural sites. Am J Trop Med Hyg 1979;28(4):697–700. https://doi.org/10.4269/ajtmh.1979.28.697

Return to footnote 52 referrer

Footnote 53

Denton JF, Disalvo AF. Isolation of Blastomyces dermatitidis from natural sites at Augusta, Georgia. Am J Trop Med Hyg 1964;13:716–22. https://doi.org/10.4269/ajtmh.1964.13.716

Return to footnote 53 referrer

Footnote 54

Koske SE, Kocharian A, Kazmierczak JJ, Gibbons-Burgener SN, Dieckman JL, Klos RF, Wohlt J, Meece JK, Anderson JL, Davis JP. Investigation of a Large Outbreak of Blastomycosis Caused By Blastomyces Gilchristii Among Recreational River Tubers, Wisconsin, 2015. CSTE 2017. https://cste.confex.com/cste/2017/webprogram/Paper8047.html

Return to footnote 54 referrer

Footnote 55

Klein BS, Vergeront JM, Weeks RJ, Kumar UN, Mathai G, Varkey B, Kaufman L, Bradsher RW, Stoebig JF, Davis JP. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med 1986;314(9):529–34. https://doi.org/10.1056/NEJM198602273140901

Return to footnote 55 referrer

Footnote 56

Klein BS, Vergeront JM, DiSalvo AF, Kaufman L, Davis JP. Two outbreaks of blastomycosis along rivers in Wisconsin. Isolation of Blastomyces dermatitidis from riverbank soil and evidence of its transmission along waterways. Am Rev Respir Dis 1987;136(6):1333–8. https://doi.org/10.1164/ajrccm/136.6.1333

Return to footnote 56 referrer

Footnote 57

Proctor ME, Klein BS, Jones JM, Davis JP. Cluster of pulmonary blastomycosis in a rural community: evidence for multiple high-risk environmental foci following a sustained period of diminished precipitation. Mycopathologia 2002;153(3):113–20. https://doi.org/10.1023/A:1014515230994

Return to footnote 57 referrer

Footnote 58

McTaggart LR, Brown EM, Richardson SE. Phylogeographic Analysis of Blastomyces dermatitidis and Blastomyces gilchristii Reveals an Association with North American Freshwater Drainage Basins. PLoS One 2016;11(7):e0159396. https://doi.org/10.1371/journal.pone.0159396

Return to footnote 58 referrer

Footnote 59

McDonough ES, Wisniewski TR, Penn LA, Chan DM, McNamara WJ. Preliminary studies on conidial liberation of Blastomyces dermatitidis and Histoplasma capsulatum. Sabouraudia 1976;14(2):199–204. https://doi.org/10.1080/00362177685190271

Return to footnote 59 referrer

Footnote 60

Baumgardner DJ, Burdick JS. An outbreak of human and canine blastomycosis. Rev Infect Dis 1991;13(5):898–905. https://doi.org/10.1093/clinids/13.5.898

Return to footnote 60 referrer

Footnote 61

De Groote MA, Bjerke R, Smith H, Rhodes LV 3rd. Expanding epidemiology of blastomycosis: clinical features and investigation of 2 cases in Colorado. Clin Infect Dis 2000;30(3):582–4. https://doi.org/10.1086/313717

Return to footnote 61 referrer

Footnote 62

Pfister JR, Archer JR, Hersil S, Boers T, Reed KD, Meece JK, Anderson JL, Burgess JW, Sullivan TD, Klein BS, Wheat LJ, Davis JP. Non-rural point source blastomycosis outbreak near a yard waste collection site. Clin Med Res 2011;9(2):57–65. https://doi.org/10.3121/cmr.2010.958

Return to footnote 62 referrer

Footnote 63

MacDonald PD, Langley RL, Gerkin SR, Torok MR, MacCormack JN. Human and canine pulmonary blastomycosis, North Carolina, 2001-2002. Emerg Infect Dis 2006;12(8):1242–4. https://doi.org/10.3201/eid1208.050781

Return to footnote 63 referrer

Footnote 64

Centers for Disease Control and Prevention. Risk Factors for Blastomycosis. Atlanta, GA: CDC; 2024. https://www.cdc.gov/blastomycosis/risk-factors/index.html

Return to footnote 64 referrer

Footnote 65

Alhatem A, Smith KC. Primary Cutaneous Blastomycosis. N Engl J Med 2022;386(18):e49. https://doi.org/10.1056/NEJMicm2116178

Return to footnote 65 referrer

Footnote 66

Vaaler AK, Bradsher RW, Davies SF. Evidence of subclinical blastomycosis in forestry workers in northern Minnesota and northern Wisconsin. Am J Med 1990;89(4):470–6. https://doi.org/10.1016/0002-9343(90)90378-Q

Return to footnote 66 referrer

Footnote 67

Van Howe RS. The Billirud Mill Blastomycosis Outbreak: Comparison to Historical Controls. Med Mycol 2023:myad123. https://doi.org/10.1093/mmy/myad123

Return to footnote 67 referrer

Footnote 68

Ireland M, Klumb C, Smith K, Scheftel J. Blastomycosis in Minnesota, USA, 1999-2018. Emerg Infect Dis 2020;26(5):866–75. https://doi.org/10.3201/eid2605.191074

Return to footnote 68 referrer

Footnote 69

Cockerill FR 3rd, Roberts GD, Rosenblatt JE, Utz JP, Utz DC. Epidemic of pulmonary blastomycosis (Namekagon fever) in Wisconsin canoeists. Chest 1984;86(5):688–92. https://doi.org/10.1378/chest.86.5.688

Return to footnote 69 referrer

Footnote 70

Centers for Disease Control and Prevention (CDC). Blastomycosis--Wisconsin, 1986-1995. MMWR Morb Mortal Wkly Rep 1996;45(28):601–3. https://www.cdc.gov/mmwr/preview/mmwrhtml/00043101.htm

Return to footnote 70 referrer

Footnote 71

Smith DJ, Williams SL, Benedict KM, Jackson BR, Toda M; Endemic Mycoses State Partners Group. Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis - United States, 2019. MMWR Surveill Summ 2022;71(7):1–14. https://doi.org/10.15585/mmwr.ss7107a1

Return to footnote 71 referrer

Footnote 72

McHardy I, Reagan KL, Sebastian JF, Barker B, Bays DJ, Dandekar S, Cohen SH, Jennings KE, Sykes J, Thompson GR 3rd. Sex differences in the susceptibility to coccidioidomycosis. Open Forum Infect Dis 2022;9(3):ofab543. https://doi.org/10.1093/ofid/ofab543

Return to footnote 72 referrer

Footnote 73

Gray NA, Baddour LM. Cutaneous inoculation blastomycosis. Clin Infect Dis 2002;34(10):E44–9. https://doi.org/10.1086/339957

Return to footnote 73 referrer

Footnote 74

Gnann JW Jr, Bressler GS, Bodet CA 3rd, Avent CK. Human blastomycosis after a dog bite. Ann Intern Med 1983;98(1):48–9. https://doi.org/10.7326/0003-4819-98-1-48

Return to footnote 74 referrer

Footnote 75

Larsh HW, Schwarz J. Accidental inoculation blastomycosis. Cutis 1977;19(3):334–5.

Return to footnote 75 referrer

Footnote 76

Bhatia M, Kak V, Patel P, Slota A. Thinking Beyond Bacterial Infection: A Case of Cutaneous Blastomycosis. Cureus 2022;14(1):e21634. https://doi.org/10.7759/cureus.21634

Return to footnote 76 referrer

Footnote 77

Craig MW, Davey WN, Green RA. Conjugal blastomycosis. Am Rev Respir Dis 1970;102(1):86–90.

Return to footnote 77 referrer

Footnote 78

Farber ER, Leahy MS, Meadows TR. Endometrial blastomycosis acquired by sexual contact. Obstet Gynecol 1968;32(2):195–9.

Return to footnote 78 referrer

Footnote 79

Lemos LB, Soofi M, Amir E. Blastomycosis and pregnancy. Ann Diagn Pathol 2002;6(4):211–5. https://doi.org/10.1053/adpa.2002.34729

Return to footnote 79 referrer

Footnote 80

Baker T, Patel A, Halteh P, Toussi SS, DeLaMora P, Lipner S, Schuetz AN, Hartman B. Blastomycosis during pregnancy: a case report and review of the literature. Diagn Microbiol Infect Dis 2017;88(2):145–51. https://doi.org/10.1016/j.diagmicrobio.2017.02.015

Return to footnote 80 referrer

Footnote 81

Public Health Ontario. Zygmunt A, Kus J, La Delfa A. Blastomycosis in Ontario: Public Health and Clinical Considerations. Toronto, ON: PHO; 2022. https://dev.cm.publichealthontario.ca/-/media/Event-Presentations/2022/pho-rounds-blastomycosis-ontario.pdf?rev=4eb6c79d6f4f473ebd1a36dc65128fd5&sc_lang=en

Return to footnote 81 referrer

Footnote 82

Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol 2001;5(1):1–9. https://doi.org/10.1053/adpa.2001.21473

Return to footnote 82 referrer

Footnote 83

Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA. Blastomycosis in northeast Tennessee. Chest 1998;114(2):436–43. https://doi.org/10.1378/chest.114.2.436

Return to footnote 83 referrer

Footnote 84

Azar MM, Assi R, Relich RF, Schmitt BH, Norris S, Wheat LJ, Hage CA. Blastomycosis in Indiana: Clinical and Epidemiologic Patterns of Disease Gleaned from a Multicenter Retrospective Study. Chest 2015;148(5):1276–84. https://doi.org/10.1378/chest.15-0289

Return to footnote 84 referrer

Footnote 85

Sapra A, Pham D, Ranjit E, Baig MQ, Hui J. A Curious Case of Blastomyces Osteomyelitis. Cureus 2020;12(3):e7417. https://doi.org/10.7759/cureus.7417

Return to footnote 85 referrer

Footnote 86

Friedman JA, Wijdicks EF, Fulgham JR, Wright AJ. Meningoencephalitis due to Blastomyces dermatitidis: case report and literature review. Mayo Clin Proc 2000;75(4):403–8. https://doi.org/10.4065/75.4.403

Return to footnote 86 referrer

Footnote 87

Raman Sharma R. Fungal infections of the nervous system: current perspective and controversies in management. Int J Surg 2010;8(8):591–601. https://doi.org/10.1016/j.ijsu.2010.07.293

Return to footnote 87 referrer

Footnote 88

Gonyea EF. The spectrum of primary blastomycotic meningitis: a review of central nervous system blastomycosis. Ann Neurol 1978;3(1):26–39. https://doi.org/10.1002/ana.410030106

Return to footnote 88 referrer

Footnote 89

Public Health Agency of Canada. For health professionals: Blastomycosis. Ottawa, ON: PHAC; 2016. https://www.canada.ca/en/public-health/services/diseases/blastomycosis/health-professionals-blastomycosis.html

Return to footnote 89 referrer

Footnote 90

Caldito EG, Antia C, Petronic-Rosic V. Cutaneous Blastomycosis. JAMA Dermatol 2022;158(9):1064. https://doi.org/10.1001/jamadermatol.2022.3151

Return to footnote 90 referrer

Footnote 91

Zinder R, Pitchford KL, Vlad LG, Molnar JA. Non-healing wound from disseminated blastomycosis. Wounds International 2021;12(1):39–43. https://woundsinternational.com/journal-articles/non-healing-wound-disseminated-blastomycosis/

Return to footnote 91 referrer

Footnote 92

Kauffman CA. Central Nervous System Infection with Other Endemic Mycoses: Rare Manifestation of Blastomycosis, Paracoccidioidomycosis, Talaromycosis, and Sporotrichosis. J Fungi (Basel) 2019;5(3):64. https://doi.org/10.3390/jof5030064

Return to footnote 92 referrer

Footnote 93

Carignan A, Boudhrioua C, Moreira S, Pelletier AA, Dufour K, Pépin J, Allard C, Marcoux D, Dufresne PJ. Changing Patterns of Disease Severity in Blastomyces dermatitidis Infection, Quebec, Canada. Emerg Infect Dis 2021;27(11):2810–7. https://doi.org/10.3201/eid2711.210552

Return to footnote 93 referrer

Footnote 94

Linz AM, Frost HM, Kitchner T, Anderson JL, Meece J. Clinical Presentation of Blastomycosis is Associated With Infecting Species, Not Host Genotype. Clin Med Res 2024;22(1):6–12. https://doi.org/10.3121/cmr.2024.1880

Return to footnote 94 referrer

Footnote 95

Rush B, Lother S, Paunovic B, Mooney O, Kumar A. Outcomes with severe blastomycosis and respiratory failure in the United States. Clin Infect Dis 2021;72(9):1603–7. https://doi.org/10.1093/cid/ciaa294

Return to footnote 95 referrer

Footnote 96

Williams SL, Smith DJ, Benedict K, Ahlers JR, Austin C, Birn R, Carter AM, Christophe NN, Cibulskas K, Cieslak PR, Gibbons-Burgener SN, Gosciminski M, Ireland MJ, Lazenby KV, Loftus T, Lunquest K, Mathewson AA, Nguyen AD, Oltean HN, Osborn B, Petro EM, Power DJ, Reik RR, Schlosser L, Sedivy J, Smelser CB, Chiller T, Toda M. Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis During the COVID-19 Pandemic - United States, 2019-2021. MMWR Morb Mortal Wkly Rep 2024;73(11):239–44. https://doi.org/10.15585/mmwr.mm7311a2

Return to footnote 96 referrer

Footnote 97

Villacorta Cari E, Leedy N, Ribes JA, Soria J, Myint T. Risk factors of severe blastomycosis and comparison of diagnosis and outcomes between immunocompetent and immunocompromised patients. Mycoses 2022;65(2):239–46. https://doi.org/10.1111/myc.13409

Return to footnote 97 referrer

Footnote 98

Centers for Disease Control and Prevention. Testing Algorithm for Blastomycosis. Community-Acquired Pneumonia. Atlanta, GA: CDC; 2024. https://www.cdc.gov/blastomycosis/hcp/testing-algorithm/

Return to footnote 98 referrer

Footnote 99

Richer SM, Smedema ML, Durkin MM, Brandhorst TT, Hage CA, Connolly PA, Leland DS, Davis TE, Klein BS, Wheat LJ. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein BAD-1. Clin Vaccine Immunol 2014;21(2):143–6. https://doi.org/10.1128/CVI.00597-13

Return to footnote 99 referrer

Footnote 100

Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Haydour Q, Knox KS, Kolls JK, Murad MH, Wengenack NL, Limper AH. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2019;200(5):535–50. https://doi.org/10.1164/rccm.201906-1185ST

Return to footnote 100 referrer

Footnote 101

Durkin M, Witt J, Lemonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004;42(10):4873–5. https://doi.org/10.1128/JCM.42.10.4873-4875.2004

Return to footnote 101 referrer

Footnote 102

Connolly P, Hage CA, Bariola JR, Bensadoun E, Rodgers M, Bradsher RW Jr, Wheat LJ. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vaccine Immunol 2012;19(1):53–6. https://doi.org/10.1128/CVI.05248-11

Return to footnote 102 referrer

Footnote 103

Frost HM, Novicki TJ. Blastomyces antigen detection for diagnosis and management of blastomycosis. J Clin Microbiol 2015;53(11):3660–2. https://doi.org/10.1128/JCM.02352-15

Return to footnote 103 referrer

Footnote 104

Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA; Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46(12):1801–12. https://doi.org/10.1086/588300

Return to footnote 104 referrer

Footnote 105

Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA; Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45(7):807–25. https://doi.org/10.1086/521259

Return to footnote 105 referrer

Footnote 106

Linder KA, Kauffman CA. Current and New Perspectives in the Diagnosis of Blastomycosis and Histoplasmosis. J Fungi (Basel) 2020;7(1):12. https://doi.org/10.3390/jof7010012

Return to footnote 106 referrer

Footnote 107

O’Dowd TR, Mc Hugh JW, Theel ES, Wengenack NL, O’Horo JC, Enzler MJ, Vergidis P. Diagnostic Methods and Risk Factors for Severe Disease and Mortality in Blastomycosis: A Retrospective Cohort Study. J Fungi (Basel) 2021;7(11):888. https://doi.org/10.3390/jof7110888

Return to footnote 107 referrer

Footnote 108

Spec A, Thompson GR, Miceli MH, Hayes J, Proia L, McKinsey D, Arauz AB, Mullane K, Young JA, McGwin G, McMullen R, Plumley T, Moore MK, McDowell LA, Jones C, Pappas PG. MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses-A Multicenter, Open-Label, Randomized Comparative Trial. Open Forum Infect Dis 2024;11(3):ofae010. https://doi.org/10.1093/ofid/ofae010

Return to footnote 108 referrer

Footnote 109

Leung S, Poulakos MN, Machin J. Posaconazole: An Update of Its Clinical Use. Pharmacy (Basel) 2015;3(4):210–68. https://doi.org/10.3390/pharmacy3040210

Return to footnote 109 referrer

Footnote 110

Scolarici MJ, King C, Sterkel A, Smith J, Gauthier G, Saddler C. The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility. Open Forum Infect Dis 2022;9(7):ofac220. https://doi.org/10.1093/ofid/ofac220

Return to footnote 110 referrer

Footnote 111

Smith DJ, Gold JA, Benedict K, Wu K, Lyman M, Jordan A, Medina N, Lockhart SR, Sexton DJ, Chow NA, Jackson BR, Litvintseva AP, Toda M, Chiller T. Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives. J Fungi (Basel) 2023;9(8):820. https://doi.org/10.3390/jof9080820

Return to footnote 111 referrer

Footnote 112

Ogden NH, Gachon P. Climate change and infectious diseases: what can we expect? Can Commun Dis Rep 2019;45(4):76–80. https://doi.org/10.14745/ccdr.v45i04a01

Return to footnote 112 referrer

Footnote 113

Mora C, McKenzie T, Gaw IM, Dean JM, von Hammerstein H, Knudson TA, Setter RO, Smith CZ, Webster KM, Patz JA, Franklin EC. Over half of known human pathogenic diseases can be aggravated by climate change. Nat Clim Chang 2022;12(9):869–75. https://doi.org/10.1038/s41558-022-01426-1

Return to footnote 113 referrer

Footnote 114

Gorris ME, Treseder KK, Zender CS, Randerson JT. Expansion of coccidioidomycosis endemic regions in the United States in response to climate change. Geohealth 2019;3(10):308–27. https://doi.org/10.1029/2019GH000209

Return to footnote 114 referrer

Footnote 115

Head JR, Sondermeyer-Cooksey G, Heaney AK, Yu AT, Jones I, Bhattachan A, Campo SK, Wagner R, Mgbara W, Phillips S, Keeney N, Taylor J, Eisen E, Lettenmaier DP, Hubbard A, Okin GS, Vugia DJ, Jain S, Remais JV. Effects of precipitation, heat, and drought on incidence and expansion of coccidioidomycosis in western USA: a longitudinal surveillance study. Lancet Planet Health 2022;6(10):e793–803. https://doi.org/10.1016/S2542-5196(22)00202-9

Return to footnote 115 referrer

Footnote 116

Maiga AW, Deppen S, Scaffidi BK, Baddley J, Aldrich MC, Dittus RS, Grogan EL. Mapping Histoplasma capsulatum Exposure, United States. Emerg Infect Dis 2018;24(10):1835–9. https://doi.org/10.3201/eid2410.180032

Return to footnote 116 referrer

Footnote 117

Jackson KM, Pelletier KC, Scheftel J, Kerkaert JD, Robinson SL, McDonald T, Bender JB, Knight JF, Ireland M, Nielsen K. Analysis and modeling of Blastomyces dermatitidis environmental prevalence in Minnesota using soil collected to compare basal and outbreak levels. Appl Environ Microbiol 2021;87(5):e01922–20. https://doi.org/10.1128/AEM.01922-20

Return to footnote 117 referrer

Footnote 118

Szeder V, Ortega-Gutierrez S, Frank M, Jaradeh SS. CNS blastomycosis in a young man working in fields after Hurricane Katrina. Neurology 2007;68(20):1746–7. https://doi.org/10.1212/01.wnl.0000265229.31844.45

Return to footnote 118 referrer

Footnote 119

Bethuel NW, Siddiqui N, Edmonds L. Pulmonary blastomycosis in rural Upstate New York: A case series and review of literature. Ann Thorac Med 2020;15(3):174–8. https://doi.org/10.4103/atm.ATM_86_20

Return to footnote 119 referrer

Footnote 120

Ross JJ, Koo S, Woolley AE, Zuckerman RA. Blastomycosis in New England: 5 Cases and a Review. Open Forum Infect Dis 2023;10(1):ofad029. https://doi.org/10.1093/ofid/ofad029

Return to footnote 120 referrer

Footnote 121

Greer A, Ng V, Fisman D. Climate change and infectious diseases in North America: the road ahead. CMAJ 2008;178(6):715–22. https://doi.org/10.1503/cmaj.081325

Return to footnote 121 referrer

Footnote 122

Panackal AA. Global Climate Change and Infectious Diseases: invasive Mycoses. J Earth Sci Clim Change 2011;2(2):108. https://doi.org/10.4172/2157-7617.1000108

Return to footnote 122 referrer

Footnote 123

van Rhijn N, Bromley M. The Consequences of Our Changing Environment on Life Threatening and Debilitating Fungal Diseases in Humans. J Fungi (Basel) 2021;7(5):367. https://doi.org/10.3390/jof7050367

Return to footnote 123 referrer

Footnote 124

Carignan A, Valiquette L, Laupland KB. Impact of climate change on emerging infectious diseases: implications for Canada. J Assoc Med Microbiol Infect Dis Can 2019;4(2):55–9. https://doi.org/10.3138/jammi.2018-12-10

Return to footnote 124 referrer

Footnote 125

Nnadi NE, Carter DA. Climate change and the emergence of fungal pathogens. PLoS Pathog 2021;17(4):e1009503. https://doi.org/10.1371/journal.ppat.1009503

Return to footnote 125 referrer

Footnote 126

Garcia-Solache MA, Casadevall A. Global warming will bring new fungal diseases for mammals. MBio 2010;1(1):e00061–10. https://doi.org/10.1128/mBio.00061-10

Return to footnote 126 referrer

Footnote 127

Bonifaz A, García-Salazar E, Frías-De-León MG. Climate Change Exacerbating Fungal Disease Disparities. Curr Fungal Infect Rep 2024;18(1):1–12. https://doi.org/10.1007/s12281-023-00479-9

Return to footnote 127 referrer

Footnote 128

Gnat S, Łagowski D, Nowakiewicz A, Dyląg M. A global view on fungal infections in humans and animals: infections caused by dimorphic fungi and dermatophytoses. J Appl Microbiol 2021;131(6):2688–704. https://doi.org/10.1111/jam.15084

Return to footnote 128 referrer

Footnote 129

Linz AM, Anderson JL, Meece JK. Detection of Blastomyces gilchristii via metagenomic sequencing in outbreak-associated soils. Med Mycol 2024;62(1):myad140. https://doi.org/10.1093/mmy/myad140

Return to footnote 129 referrer

Footnote 130

Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C, Liao W, Zhi K, Pan W. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci 2023;30(1):42. https://doi.org/10.1186/s12929-023-00926-2

Return to footnote 130 referrer

Footnote 131

Chandra TB, Singh BK, Jain D. Integrating patient symptoms, clinical readings, and radiologist feedback with computer-aided diagnosis system for detection of infectious pulmonary disease: a feasibility study. Med Biol Eng Comput 2022;60(9):2549–65. https://doi.org/10.1007/s11517-022-02611-2

Return to footnote 131 referrer

This work is licensed under a Creative Commons Attribution 4.0 International License

Page details

Date modified:: 2024-11-07

Language selection

Search

Perspectives on blastomycosis in Canada in the face of climate change

Submit a manuscript

About CCDR

Browse

Overview

Abstract

Introduction

Background

Objectives

Methods

Discussion

Incidence and trends in Canada

Ecological factors

Risk groups

Clinical features of blastomycosis

Laboratory diagnosis

Treatment

Impacts of climate change

Conclusion

Authors' statement

Competing interests

Acknowledgements

Funding

References

Page details